Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda and Halaven in metastatic triple-negative breast cancer
NCT02513472Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Aug 2015
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eribulin in triple negative breast cancer (TNBC), sponsored by Eisai Co., Ltd.. Started Aug 2015; status: completed.
02
Drugs
eribulin
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02513472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02513472.